MedPath

Spironolactone

Generic Name
Spironolactone
Brand Names
Aldactazide, Aldactone, Carospir, Qaialdo
Drug Type
Small Molecule
Chemical Formula
C24H32O4S
CAS Number
52-01-7
Unique Ingredient Identifier
27O7W4T232
Background

Spironolactone is a potassium-sparing diuretic. It binds to mineralocorticoid receptors and functions as aldosterone antagonists. It promotes sodium and water excretion and potassium retention. Spironolactone was originally developed purely for this ability before other pharmacodynamic properties of the drug were discovered. It is indicated to treat several conditions, including heart failure, edema, hyperaldosteronism, and hypertension. Off-label uses of spironolactone include hirsutism, female pattern hair loss, and adult acne vulgaris.

Spironolactone was developed in 1957, marketed in 1959, and approved by the FDA on January 21, 1960.

Indication

Spironolactone is indicated for the treatment of the following conditions:

As spironolactone has antiandrogenic activity, its off-label uses include the treatment of hirsutism, female pattern hair loss, and adult acne vulgaris.

Associated Conditions
Edema, Hypertension, Primary Aldosteronism, Primary Hyperaldosteronism, Secondary hyperaldosteronism, Chronic heart failure with reduced ejection fraction (NYHA Class III), Chronic heart failure with reduced ejection fraction (NYHA Class IV), Idiopathic hyperaldosteronism, Refractory Edema
Associated Therapies
Perioperative drug treatment, Maintenance therapy
Clinical Trials
Related News

Spironolactone in Covid-19 Induced ARDS

Completed
Conditions
Respiratory Distress Syndrome, Adult
Interventions
Drug: Placebo oral tablet
First Posted Date
2020-04-15
Last Posted Date
2021-10-28
Lead Sponsor
Istanbul University - Cerrahpasa (IUC)
Target Recruit Count
60
Registration Number
NCT04345887
Locations
🇹🇷

Istanbul University-Cerrahpaşa, Istanbul, Turkey

Comparison of Spironolactone and Amiloride on Home Blood Pressure in Resistant Hypertension

Phase 4
Completed
Conditions
Resistant Hypertension
Interventions
First Posted Date
2020-04-02
Last Posted Date
2024-08-26
Lead Sponsor
Yonsei University
Target Recruit Count
118
Registration Number
NCT04331691
Locations
🇰🇷

Severance Cardiovascular Hospital, Yonsei University Health System, Seoul, Korea, Republic of

Mineralocorticoid Antagonism to Stop Progression of Atrial Fibrillation (MONITOR-AF) Study

Phase 2
Conditions
Atrial Fibrillation
Interventions
Drug: Placebo oral tablet
First Posted Date
2020-03-31
Last Posted Date
2020-03-31
Lead Sponsor
National University Hospital, Singapore
Target Recruit Count
184
Registration Number
NCT04327232
Locations
🇸🇬

Ng Teng Fong General Hospital, Singapore, Singapore

🇸🇬

Changi General Hospital, Singapore, Singapore

🇸🇬

Tan Tock Seng Hospital, Singapore, Singapore

and more 1 locations

Evaluating Drug Interactions Between Doravirine With Estradiol and Spironolactone in Healthy Transgender Women

Phase 1
Completed
Conditions
Transgender Health
Gender Dysphoria
Transgender Women
Human Immunodeficiency Virus
Interventions
Drug: Doravirine/Lamivudine/Tenofovir
Other: Placebo
First Posted Date
2020-02-25
Last Posted Date
2025-03-26
Lead Sponsor
Thomas Jefferson University
Target Recruit Count
8
Registration Number
NCT04283656
Locations
🇺🇸

Clinical Research Unit at Thomas Jefferson University, Philadelphia, Pennsylvania, United States

Spironolactone to Improve Apnea and Cardiovascular Markers in Obstructive Sleep Apnea Patients

Phase 4
Withdrawn
Conditions
Obstructive Sleep Apnea
Interventions
Drug: Placebo
First Posted Date
2019-12-19
Last Posted Date
2022-04-19
Lead Sponsor
University of Michigan
Registration Number
NCT04205136
Locations
🇺🇸

The University of Michigan, Ann Arbor, Michigan, United States

Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial

Phase 2
Withdrawn
Conditions
Lymphoma
Hematopoietic and Lymphoid Cell Neoplasm
Breast Carcinoma
Sarcoma
Interventions
First Posted Date
2019-12-09
Last Posted Date
2023-05-24
Lead Sponsor
Mayo Clinic
Registration Number
NCT04190433

Spironolactone for Hidradenitis Suppurativa

Phase 4
Withdrawn
Conditions
Hidradenitis Suppurativa
Interventions
First Posted Date
2019-09-24
Last Posted Date
2020-10-26
Lead Sponsor
Medical University of South Carolina
Registration Number
NCT04100083

Does Treatment of Androgen Excess Using Spironolactone Improve Ovulatory Rates in Girls With Androgen Excess?

Early Phase 1
Recruiting
Conditions
Puberty Disorders
Ovulation Disorder
Polycystic Ovary Syndrome
Interventions
First Posted Date
2019-08-30
Last Posted Date
2023-10-27
Lead Sponsor
University of Virginia
Target Recruit Count
24
Registration Number
NCT04075149
Locations
🇺🇸

University of Virginia Center for Research in Reproduction, Charlottesville, Virginia, United States

A Registry-based Cluster Randomized Trial to Compare the Effect of Spironolactone vs. Eplerenone on Clinical Outcomes in Patients With Symptomatic Systolic Heart Failure

Phase 4
Conditions
Systolic Heart Failure
Interventions
First Posted Date
2019-06-13
Last Posted Date
2023-02-01
Lead Sponsor
Bispebjerg Hospital
Target Recruit Count
7200
Registration Number
NCT03984591
Locations
🇩🇰

Bispebjerg Hospital, Copenhagen, Denmark

Effect of Add-on Spironolactone to Losartan Versus Losartan Alone on Peritoneal Membrane Among Peritoneal Dialysis Patients

Phase 4
Conditions
End Stage Renal Disease
Peritoneal Dialysis
Interventions
First Posted Date
2019-05-17
Last Posted Date
2019-09-04
Lead Sponsor
Chiang Mai University
Target Recruit Count
84
Registration Number
NCT03953950
Locations
🇹🇭

Pharmacoepidemiology and Statistics Research Center, Faculty of Pharmacy, Chiang Mai University, Chiang Mai, Thailand

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy